慢性肾脏病合并丙型肝炎病毒感染诊断、治疗和预防的临床实践指南(2023年版)

丙型肝炎病毒(HCV)感染在慢性肾脏病(CKD)患者中高发，CKD患者在抗HCV治疗方面具有特殊性。随着直接抗病毒药物(DAA)问世并广泛应用于临床，CKD患者合并HCV感染的预后获得极大改善。近年来HCV治疗领域进展迅速，多种DAA相继在国内获批上市。为此，我国肾脏病、感染病、肝病和感控专家在2019年发表的《慢性肾脏病合并丙型肝炎病毒感染诊断及治疗的专家共识》基础上，以国内外临床研究进展为依据，结合现阶段我国实际情况，更新形成了本指南，以期为CKD合并HCV感染患者的规范化诊治提供指导性建议。

Clinical practice guideline for the diagnosis, treatment and prevention of hepatitis C virus infection in patients with chronic kidney disease (2023)

Hepatitis C virus (HCV) infection is of high prevalence among patients with chronic kidney disease (CKD). There are many unique features in anti-HCV treatment of CKD patients. With the advent of direct-acting antiviral agents (DAAs) and their widely application in clinic practice, the prognosis of CKD patients with HCV infection has been greatly improved. In recent years, rapid progress has been made in HCV treatment, and many DAAs have been approved for marketing in China. Therefore, based on The expert consensus for the diagnosis and treatment of hepatitis C virus infection in patients with chronic kidney disease published in 2019, combined with the domestic and foreign progress of clinical research and the national situation in China at present, a panel of experts specialized in nephrology, infectious disease, hepatology and infection control have updated and issued this guideline, to provide guidance for the standardized diagnosis and treatment of HCV infection in CKD patients.